24-11-2020
eHealth Ventures, a Leading Digital Health Investor, and Assuta Ashdod, a Top Medical Center, Announce Strategic Collaboration Agreemen

eHealth Ventures, an early stage investor focused on digital health and manager of an incubator operating under license from the Israeli Innovation Authority is proud to announce a strategic collaboration agreement with Assuta Ashdod – a top tertiary hospital and the newest public hospital established in Israel, located in the southern city of Ashdod.

The Medical Center will serve as a “preferred nation” clinical development and validation site for the incubator and its portfolio companies, for the purpose of evaluation, co-development, and performance of clinical and validation studies in Israel.

At the same time, the incubator will serve as a go-to extension for the innovation activities within the Medical Center, led by Dr. Gil Levy, director of Medical Innovation in Assuta Ashdod,  so that novel developments that are conceived by the medical staff will be directed to eHV for screening, evaluation, and funding as potential portfolio companies. Following screening, in the event of a strong fit with the incubator criteria for investment, and subject to further approval by the Israel Innovation Authority – the incubator will establish a new portfolio company and fund the project.

Furthermore, and based on a successful acceleration program which took place at the Assuta Medical Center earlier this year – the incubator and its team will continue to share best practices and accumulated knowledge in the field of digital health innovation and entrepreneurship and execute seminars, meetups and other events with the Assuta team, aimed at establishing a shared, broad body of knowledge in this field.

As an inaugural, important test case the parties have decided to plan and execute a clinical study by Ophthalmic Sciences Ltd. – an eHV portfolio company developing a home-based device for the measurement of intraocular pressure – a key biomarker for diagnosis and treatment of Glaucoma. The study will take place in the Assuta Ashdod Ophthalmology Department during Q1/21, subject to receipt of all approvals and agreement on all commercial terms.

Dr. Joseph Rosenblum, Chief Medical Officer of the eHealth Ventures incubator commented on this important agreement: “As we expand our abilities on the financial and technological side and recruit more companies into the incubator as part of our portfolio, it is critical that we connect these promising ventures to the “real world” of medicine health care. This must be done by linking them to leading medical centers and top clinical professionals in Israel and overseas. We are proud to collaborate with this new, top of the line Medical Center and we are confident it will contribute tremendous value to our portfolio companies.”

Dr. Erez Barenboim, Chief Executive Officer of the Assuta Ashdod Medical Center added: “Innovation is a key element of our DNA with the Assuta Ashdod Medical Center. Some of our top medical staff is engaged in entrepreneurship and we are happy  to encourage this important initiative by linking the center to a top incubator and VC, with many years of experience and know-how in the field of bringing novel medical ideas, technologies and products to the market. We look forward to a fruitful and long relationship that will benefit the center, its staff and ultimately – the patients and the healthcare system”.

 

For more information :

Ophir Shahaf – VP BD, eHealth Ventures  ophir@ehv.health

Gil Levy MD – Director, Dept. of Medical Innovation, Assuta Ashdod gille@assuta.co.il

 

The eHV incubator / VC and Assuta will collaborate on deal flow screening, clinical studies, go-to-market, and commercialization – adding significant value to the current and future eHV portfolio companies

 
 
 
 
NEWS
We move fast and push our companies to move faster.
Timing is everything - we get it.
For all news items
eHealth Ventures by Numbers:
15
Portfolio Companies
1300
Companies Reviewed
 
 
115
Years of experience for 4 principles
 
7
X
Fair Value Appreciation on Portfolio
Partners & Collaborators